The binding epitope of sintilimab on PD-1 revealed by AbMap
Mingliang Ma,Huan Qi,Chuansheng Hu,Zhaowei Xu,Fanlin Wu,Nan Wang,Danyun Lai,Yang Li,Hainan Zhang,Hewei Jiang,Qingfeng Meng,Shujuan Guo,Yani Kang,Xiaodong Zhao,Hua Li,Sheng-ce Tao
DOI: https://doi.org/10.1093/abbs/gmab020
IF: 3.7
2021-02-26
Acta Biochimica et Biophysica Sinica
Abstract:Abstract PD-1 plays an important role as an immune checkpoint. Sintilimab is a newly approved PD-1 antibody for cancer immunotherapy with an unknown binding epitope on PD-1. In this study, to elucidate the molecular mechanism by which sintilimab blocks PD-1 activation, we applied Antibody binding epitope Mapping (AbMap) to identify the binding epitope of sintilimab. An epitope was successfully identified, i.e. SLAPKA, aa 127–132. By constructing a series of point mutations, the dominant residues S127, L128, A129, P130, and A132 of PD-1 were further validated by western blot analysis, biolayer interferometry, and flow cytometry. Structural analysis showed that the epitope is partially within the binding interface of PD-1 and PD-L1, and this epitope also partially overlaps with that of nivolumab and pembrolizumab. These results demonstrate that sintilimab can attenuate PD-1 activation by directly competing with the interaction between PD-1 and PD-L1 through binding with the key residues of the FG loop on PD-1. This study also demonstrates the high efficiency and accuracy of AbMap for determining the binding epitope of therapeutic antibodies.
biochemistry & molecular biology,biophysics